TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29287667

Group type: EXPERIMENTAL
Intervention: Universal sexual violence (SV) education delivered by trained CHC staff to all students seeking care.
Number of subjects: 2292

Group type: COMPARATOR
Intervention: Information about drinking responsibly provided at control sites.
Number of subjects: 2292
Study: 26980000

Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (MH) at 34°C
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control at 36°C
Number of subjects: 43
Study: 24423324

Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 40 mg/28 days
Number of subjects: 358

Group type: COMPARATOR
Intervention: Octreotide LAR 20 mg/28 days
Number of subjects: 358
Study: 20877300

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 706

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 706
Study: 17118706

Group type: EXPERIMENTAL
Intervention: Contrast Water Immersion (CWI)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 22
Study: 14670573

Group type: EXPERIMENTAL
Intervention: Neglect group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Right-hemisphere stroke subjects without neglect
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual performance analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lesion analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual analyses
Number of subjects: 0
Study: 11339108

Group type: EXPERIMENTAL
Intervention: hydrogen reduced iron plus NaFe(III)EDTA (EDTA:Fe 1:2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: hydrogen reduced iron
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: hydrogen reduced iron plus Na2EDTA (EDTA:Fe 1:2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: hydrogen reduced iron plus NaFe(III)EDTA (EDTA:Fe 1:3)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: hydrogen reduced iron plus ascorbic acid (15 mg)
Number of subjects: 20
Study: 10950469

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7699155

Group type: EXPERIMENTAL
Intervention: Teicoplanin plus netilmicin
Number of subjects: 56

Group type: COMPARATOR
Intervention: Vancomycin plus netilmicin
Number of subjects: 56
Study: 3588053

Group type: EXPERIMENTAL
Intervention: Piperacillin 600 mg/kg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Piperacillin 900 mg/kg/day
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Piperacillin (both dosages)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Piperacillin (total daily dosages)
Number of subjects: 46
Study: 31609286

Group type: EXPERIMENTAL
Intervention: Digital simulator
Number of subjects: 13

Group type: COMPARATOR
Intervention: Textbook
Number of subjects: 13
Study: 28497478

Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Dapoxetine (30 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined dapoxetine (30 mg) with sildenafil citrate (50 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 28169811

Group type: EXPERIMENTAL
Intervention: Pediatric Peripheral Intravenous Infiltration Scale (PIV Scale)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Clinical judgment only
Number of subjects: 66
Study: 24919561

Group type: EXPERIMENTAL
Intervention: Participatory supportive return to work program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 0
Study: 22676205

Group type: EXPERIMENTAL
Intervention: Regular walking exercise program (3 times per week for 50 min for 6 months) and education program on diet control (once per week for 20 min for 4 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 20464479

Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide, epirubicin and fluorouracil)
Number of subjects: 773

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate and fluorouracil)
Number of subjects: 773
Study: 18395395

Group type: EXPERIMENTAL
Intervention: Self-efficacy in overcoming barriers to physical activity
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Self-efficacy in making time for activity
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Self-efficacy in sticking with physical activity
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Social support and competing demands
Number of subjects: 61
Study: 15728210

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (2 g/d)
Number of subjects: 5091

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5091
Study: 15540741

Group type: EXPERIMENTAL
Intervention: Bicalutamide (150 mg)
Number of subjects: 1218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1218
Study: 11386498

Group type: EXPERIMENTAL
Intervention: Inositol (up to 18 g/day)
Number of subjects: 20
Study: 9155816

Group type: EXPERIMENTAL
Intervention: Device A (dental device designed to increase vertical dimension and protrude the mandible)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Device B (dental device designed to minimally increase vertical opening without protruding the mandible)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Device A (for subjects who previously used Device B)
Number of subjects: 24
Study: 7956987

Group type: EXPERIMENTAL
Intervention: Oat gum (2.9 g beta-glucan)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 20
Study: 3602212

Group type: EXPERIMENTAL
Intervention: Bromocriptine (single dose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30325021

Group type: EXPERIMENTAL
Intervention: Lycopene supplementation
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Lycopene dietary advice
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Genetically instrumented SD increase in pyruvate
Number of subjects: 128
Study: 27912155

Group type: EXPERIMENTAL
Intervention: dual-task motor-cognitive training
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: single-task cognitive training
Number of subjects: 60

Group type: COMPARATOR
Intervention: not applicable
Number of subjects: 60
Study: 26573153

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (P6, ST36, LI4)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 153
Study: 23239139

Group type: EXPERIMENTAL
Intervention: Losmapimod, 7.5 mg BID for 28 days
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 21689371

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 7500 IU twice daily until birth or 34 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 32
Study: 17949428

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 0
Study: 16940833

Group type: EXPERIMENTAL
Intervention: Seven‐valent pneumococcal conjugate vaccine
Number of subjects: 37868

Group type: COMPARATOR
Intervention: Control radiographs
Number of subjects: 37868
Study: 12661789

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels in patients with cerebrovascular disease
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Fibronectin (FN) levels in patients with cerebrovascular disease
Number of subjects: 133

Group type: COMPARATOR
Intervention: Healthy controls (CRP and FN levels)
Number of subjects: 133
Study: 10639541

Group type: EXPERIMENTAL
Intervention: 80 percent inspired oxygen
Number of subjects: 500

Group type: COMPARATOR
Intervention: 30 percent inspired oxygen
Number of subjects: 500
Study: 9180362

Group type: EXPERIMENTAL
Intervention: THC (delta9 tetrahydrocannabinol)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: THC (lower dose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: THC (higher dose)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 32
Study: 1584611

Group type: COMPARATOR
Intervention: Q = 0 lenses (conventional spherical surface)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Q = -0.26 lenses (similar to the average corneal asphericity)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Q = -0.51 lenses
Number of subjects: 12

Group type: COMPARATOR
Intervention: Q = 0 lenses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Q = -0.26 lenses
Number of subjects: 12
Study: 3888591

Group type: EXPERIMENTAL
Intervention: 100 micrograms levothyroxine
Number of subjects: 39

Group type: COMPARATOR
Intervention: 500 micrograms iodide
Number of subjects: 39
Study: 30995574

Group type: EXPERIMENTAL
Intervention: Antimicrobial towel
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Soap and water + treated towel
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Water only + treated towel
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Soap and water + air dry
Number of subjects: 125

Group type: COMPARATOR
Intervention: Untreated (placebo) towel
Number of subjects: 125
Study: 27604532

Group type: COMPARATOR
Intervention: Intramuscular group (intramuscular injection of betamethasone and US-guided intratenosynovial isotonic saline injection)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intratenosynovial group (saline intramuscularly and US-guided intratenosynovial betamethasone injection)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intramuscular group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intratenosynovial group
Number of subjects: 50
Study: 25786903

Group type: EXPERIMENTAL
Intervention: Post-fundoplication patients
Number of subjects: 28

Group type: COMPARATOR
Intervention: GERD patients
Number of subjects: 28
Study: 24565123

Group type: EXPERIMENTAL
Intervention: Ketamine (5 mcg.kg(‐1).min(‐1)) and remifentanil (0.4 mcg.kg(‐1).min(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil (0.4 mcg.kg(‐1).min(‐1)) and saline solution
Number of subjects: 40
Study: 21885625

Group type: EXPERIMENTAL
Intervention: Long-acting β-agonists
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 1200
Study: 19506540

Group type: EXPERIMENTAL
Intervention: Ultrasonic arterial mapping
Number of subjects: 130

Group type: COMPARATOR
Intervention: Arteriography
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Ultrasonic arterial mapping and arteriography
Number of subjects: 130
Study: 17321595

Group type: EXPERIMENTAL
Intervention: Clinical management/pharmacotherapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Clinical management/placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Monthly maintenance IPT/pharmacotherapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Monthly maintenance IPT/placebo
Number of subjects: 116
Study: 15204461

Group type: EXPERIMENTAL
Intervention: Electromagnetic field treatment with calcitonin and exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment with calcitonin and exercise
Number of subjects: 40
Study: 11355928

Group type: EXPERIMENTAL
Intervention: 60 mg/m2 daunorubicin for 3 days in combination with standard dose Ara‐C and 6‐thioguanine for induction and consolidation, followed by prolonged monthly maintenance chemotherapy for at least 1 year.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-myeloablative preparative regimens for allogeneic transplantation.
Number of subjects: 0
Study: 9476677

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia combined with general anaesthesia (group I)
Number of subjects: 16

Group type: COMPARATOR
Intervention: High‐dose fentanyl anaesthesia (group II)
Number of subjects: 16
Study: 7945128

Group type: EXPERIMENTAL
Intervention: LBNP at -15 mm Hg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LBNP at -35 mm Hg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LBNP at -45 mm Hg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LBNP up to -25 mm Hg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LBNP above -25 mm Hg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LBNP up to -35 mm Hg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Greater levels of LBNP
Number of subjects: 10
Study: 3147950

Group type: EXPERIMENTAL
Intervention: Rioprostil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30721998

Group type: EXPERIMENTAL
Intervention: Music therapy interventions; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training music intervention providers; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention delivery supervision; details on dosage and duration not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment of intervention protocol adherence; details on dosage and duration not available.
Number of subjects: 0
Study: 28159015

Group type: EXPERIMENTAL
Intervention: 100 μg IC43 without adjuvant
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 100 μg IC43 with adjuvant
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200 μg IC43 with adjuvant
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24950745

Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 28

Group type: COMPARATOR
Intervention: Both nitroprusside and remifentanil
Number of subjects: 28
Study: 23553752

Group type: EXPERIMENTAL
Intervention: PEG‐IFN therapy
Number of subjects: 803
Study: 21888291

Group type: EXPERIMENTAL
Intervention: Three-stage educational strategy (critical reading guide resolution, creative discussion, group discussion)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Two-stage educational strategy (guide resolution and group discussion)
Number of subjects: 57
Study: 19860553

Group type: EXPERIMENTAL
Intervention: bimatoprost (1 drop QD)
Number of subjects: 44

Group type: COMPARATOR
Intervention: latanoprost/timolol (1 drop QD)
Number of subjects: 44
Study: 17013468

Group type: EXPERIMENTAL
Intervention: 10 mg melatonin and 50 mg zinc acetate
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 10 mg melatonin and 50 mg zinc acetate in addition to metformin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 14665794

Group type: EXPERIMENTAL
Intervention: Chart rating method for identifying and classifying MUS patients
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Chart rating method for identifying somatization and minor acute illness (MAI)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Chart rating method for quantifying medical comorbidities in MUS patients
Number of subjects: 206
Study: 14960215

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for insomnia (comprising sleep hygiene, stimulus control, relaxation and cognitive therapy components)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) for insomnia
Number of subjects: 209

Group type: COMPARATOR
Intervention: No additional treatment (control group)
Number of subjects: 209
Study: 10467999

Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated fatty acid-supplemented preterm infant formula
Number of subjects: 288

Group type: COMPARATOR
Intervention: Unsupplemented control formula
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 288
Study: 8706196

Group type: EXPERIMENTAL
Intervention: Pre‐induction volume loading (12 ml x kg(‐1) Ringer's lactate)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pre‐induction ephedrine sulphate (70 micrograms x kg(‐1) iv)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 36
Study: 2194304

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (2 x 1.2 Gy/day, five days/week, total dose 74.4 to 79.2 Gy) with simultaneous Cisplatinum (20 mg/m2 day, i.v., five days in the first and fifth week of the radiotherapy)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy with Cisplatinum
Number of subjects: 22
Study: 157893

Group type: EXPERIMENTAL
Intervention: Vioform cream, Locacorten‐Vioform cream, Vioform‐Hydrocortisone cream (topical application of 30 mg clioquinol each)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Oral administration of clioquinol (30 mg)
Number of subjects: 4
Study: 31186189

Group type: COMPARATOR
Intervention: Control (non-risk related video)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Disease (influenza) risk video
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Intervention (vaccine) risk video
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Non-specific (air pollution) risk video
Number of subjects: 800
Study: 27380904

Group type: EXPERIMENTAL
Intervention: CCTA without vasodilator
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CCTA with IV nitrate infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Catheterized ergonovine provocation test
Number of subjects: 20
Study: 27330723

Group type: EXPERIMENTAL
Intervention: 50 mg ipragliflozin
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 24598046

Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine (2 mg/kg) and Midazolam (0.5 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine and Midazolam
Number of subjects: 36
Study: 23103010

Group type: EXPERIMENTAL
Intervention: Rigid plate fixation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Wire cerclage
Number of subjects: 140
Study: 18841327

Group type: EXPERIMENTAL
Intervention: Weekly oxaliplatin 60 mg/m(2) and 5-fluorouracil 225 mg/m(2) daily throughout radiation therapy
Number of subjects: 14
Study: 17548049

Group type: EXPERIMENTAL
Intervention: CS‐US pairings
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Unpaired/non‐contingent CS and US presentations
Number of subjects: 42

Group type: COMPARATOR
Intervention: CS‐only
Number of subjects: 42
Study: 16032519

Group type: EXPERIMENTAL
Intervention: Measurement of C-reactive protein (CRP) in asymptomatic subjects at intermediate risk for future coronary events (10-year risk of 10-20%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emerging biomarkers including Lipoprotein-associated phospholipase A (2) (Lp-PLA (2))
Number of subjects: 0
Study: 12532167

Group type: EXPERIMENTAL
Intervention: Vascular Brachytherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 0
Study: 9806255

Group type: EXPERIMENTAL
Intervention: 0.25 mg Cetrorelix
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 0.50 mg Cetrorelix
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 1.00 mg Cetrorelix
Number of subjects: 36
Study: 7700286

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 114

Group type: COMPARATOR
Intervention: No myelosuppressive therapy (Control)
Number of subjects: 114
Study: 29778918

Group type: EXPERIMENTAL
Intervention: SHUTi (internet-based cognitive behavioral therapy for insomnia)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Online patient education condition (control)
Number of subjects: 303
Study: 27894289

Group type: EXPERIMENTAL
Intervention: PRASE intervention (Patient Reporting & Action for a Safe Environment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRASE intervention
Number of subjects: 0
Study: 25369488

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus sargramostim
Number of subjects: 245

Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 245
Study: 24237188

Group type: EXPERIMENTAL
Intervention: PC-18 at 37.5 mg by mouth two times per day (PO bid) for 3 weeks (induction phase)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PC-18 at the same dose (37.5 mg PO bid) during the maintenance phase
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo during the maintenance phase
Number of subjects: 40
Study: 20958145

Group type: EXPERIMENTAL
Intervention: Combination treatment (CT) with allopurinol (100‐200 mg/day) and citrate preparation (3 g/day) for 12 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Allopurinol monotherapy (MT) (100‐200 mg/day) for 12 weeks
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Combination treatment (CT) with allopurinol and citrate preparation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Allopurinol monotherapy (MT)
Number of subjects: 70
Study: 18289234

Group type: EXPERIMENTAL
Intervention: Local anaesthetic warmed to 37 degrees C
Number of subjects: 140

Group type: COMPARATOR
Intervention: Local anaesthetic stored at room temperature (control group)
Number of subjects: 140
Study: 17145540

Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (IMRT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Three-Dimensional Conformal Radiation Therapy (3D-CRT)
Number of subjects: 31
Study: 12932071

Group type: EXPERIMENTAL
Intervention: Propofol 15 mg (1.5 mL) in Group P
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Midazolam 1 mg in Group M1
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg in Group M2
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg in Group O
Number of subjects: 453
Study: 10731452

Group type: EXPERIMENTAL
Intervention: Hospital-based smoking cessation program (bedside counseling + 7 telephone calls over 6 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Minimal care (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low self-efficacy with no intervention
Number of subjects: 100
Study: 9013096

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1524860

Group type: EXPERIMENTAL
Intervention: Unannounced simulated patient evaluators (SPEs) observing physician practices
Number of subjects: 65